Abstract: Methods are disclosed for screening sulfated polysaccharides to identify one or more therapeutic agents that can be used for the treatment of a variety of disorders that affect the glycocalyx of a subject. A glycocalyx disease inhibitor identified by the method may increase the production of heparin sulfate or of one or more heparin sulfate proteins in the glycocalyx of at least one endothelial or other vascular cell.

Abstract: Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

Abstract: Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

Abstract: The present invention is directed to a composition comprising a therapeutically effective amount of exogenous heparin and arginine or physiologically acceptable salts thereof which is used in the treatment and prevention of cardiovascular diseases or disorders.

Abstract: A method for inhibiting the effects of cardiovascular disorders and diseases in a host susceptible to or suffering from a cardiovascular disorder or disease comprising administering to the host, a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a therapeutically effective amount of a second substance characterized as simulating an arginine-like effect; and a formulation for use in treating a host susceptible to or suffering from the effects of cardiovascular disorders and diseases comprising a therapeutically effective amount of a first substance characterized as simulating a heparin-like effect, and a second substance characterized an simulating an arginine-like effect, an described.